Acadian Asset Management LLC reduced its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 98.3% during the second quarter, Holdings Channel reports. The firm owned 9,399 shares of the biopharmaceutical company’s stock after selling 540,907 shares during the period. Acadian Asset Management LLC’s holdings in Vanda Pharmaceuticals were worth $154,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in VNDA. AQR Capital Management LLC bought a new stake in shares of Vanda Pharmaceuticals during the fourth quarter worth approximately $223,000. Teachers Advisors LLC boosted its stake in shares of Vanda Pharmaceuticals by 8.0% in the fourth quarter. Teachers Advisors LLC now owns 530,681 shares of the biopharmaceutical company’s stock worth $8,464,000 after buying an additional 39,340 shares during the period. Fox Run Management L.L.C. bought a new stake in shares of Vanda Pharmaceuticals during the first quarter worth approximately $266,000. Rice Hall James & Associates LLC boosted its stake in shares of Vanda Pharmaceuticals by 2.7% in the first quarter. Rice Hall James & Associates LLC now owns 27,624 shares of the biopharmaceutical company’s stock worth $387,000 after buying an additional 739 shares during the period. Finally, Columbus Circle Investors boosted its stake in shares of Vanda Pharmaceuticals by 6.7% in the first quarter. Columbus Circle Investors now owns 91,049 shares of the biopharmaceutical company’s stock worth $1,275,000 after buying an additional 5,742 shares during the period. 90.84% of the stock is owned by institutional investors.
Vanda Pharmaceuticals Inc. (NASDAQ VNDA) traded down 0.460% on Thursday, reaching $16.225. The company’s stock had a trading volume of 109,575 shares. Vanda Pharmaceuticals Inc. has a 12 month low of $11.58 and a 12 month high of $18.00. The company’s market cap is $727.82 million. The stock’s 50 day moving average price is $16.19 and its 200 day moving average price is $14.77.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The firm had revenue of $42.06 million during the quarter, compared to the consensus estimate of $40.31 million. During the same period last year, the business posted $0.01 EPS. The business’s revenue was up 16.7% compared to the same quarter last year. Equities research analysts forecast that Vanda Pharmaceuticals Inc. will post ($0.47) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Acadian Asset Management LLC Lowers Position in Vanda Pharmaceuticals Inc. (VNDA)” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.com-unik.info/2017/08/17/acadian-asset-management-llc-lowers-position-in-vanda-pharmaceuticals-inc-vnda.html.
A number of equities research analysts recently commented on the company. Zacks Investment Research raised Vanda Pharmaceuticals from a “sell” rating to a “strong-buy” rating and set a $18.00 price objective for the company in a research note on Tuesday, August 8th. Jefferies Group LLC reaffirmed a “buy” rating and set a $21.00 price objective on shares of Vanda Pharmaceuticals in a research note on Thursday, May 25th. BidaskClub cut Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. TheStreet raised Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Friday, May 12th. Finally, Piper Jaffray Companies set a $23.00 price objective on Vanda Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $21.33.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).
What are top analysts saying about Vanda Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vanda Pharmaceuticals Inc. and related companies.